1. Introduction {#sec1}
===============

Traditional Chinese medicine (TCM) has been adopted to treat the Chinese for thousands of years on the basis of some classic Chinese medicine textbooks, including*Huang Ti Nei Jing* ("The Inner Cannon of Huangti") \[[@B1]\],*Shénnóng Běn Cǎo Jīng* \[[@B2]\], and*Shang Han Za Bing Lun* ("Treatise on Cold Damage Disorders") \[[@B3]\].*Shang Han Za Bing Lun* is a Chinese medical treatise written by Zhang Zhongjing before AD 220, at the end of the Han dynasty. The treatise is the oldest comprehensive clinical textbook in the world containing principles, methods, formulas, and medicine and is the clinical literature of TCM theory with practice. To obtain the appropriate decoction for a particular ZHENG requires a diagnostic system, namely, the Decoction ZHENG proposed in*Shang Han Za Bing Lun*. Through the methods of inspection, listening, smelling, inquiry, and palpation, physicians collect information on patients to identify their TCM ZHENGs according to their personal experience and then treat these patients with herbs, which is called decoction. The methods applied in TCM have been criticized as insufficiently scientific. To overcome this weakness, we conducted systems biology research to differentiate TCM ZHENGs.

Systems biology-based diagnostic principles can be used to support the relationship between TCM and current biomedicine \[[@B4], [@B5]\]. From the perspective of gene expression profile, TCM ZHENGs differentiation is closely related to gene polymorphisms and differences in gene expression profile. Therefore, applying advanced sequencing techniques and cDNA microarray studies can help to clarify the biological basis of TCM ZHENGs \[[@B4]\]. For example, by using microarray, real-time polymerase chain reaction, and enzyme-linked immunosorbent assay technologies,*Shen Yang Xu ZHENG* has been determined to be involved with the gene level \[[@B6]\] and may be primarily attributed to the insufficient activity of the mitogen-activated protein kinase (MAPK) pathway \[[@B7]\]. The*cold* ZHENG was discovered to be possibly caused by a physiological imbalance and disorder of metabolite processes by using microarray technology \[[@B8]\]. Human mRNAs in peripheral blood mononuclear cells (PBMCs) were extracted for microarray experiments to analyze differently expressed gene expressions for TCM*cold* and*hot ZHENG* differentiation \[[@B9]--[@B11]\].

In this study, we investigated the syndromes of*Sini* decoction pattern (SDP).*Sini* decoction was first mentioned in*Shang Han Za Bing Lun Sini* decoction consisting of three herbs: fresh*Aconitum carmichaelii*, dry*Zingiber officinale*, and*Glycyrrhiza uralensis*, which was characterized as a remedy to have essential effect of recuperating the patients from collapse. It was used to treat the syndrome of displaying coldness on the extremities, pulse feels deep or faint, continuous diarrhea with undigested cereal, profuse perspiration, abdominal fullness and distention, vomiting, and lethargy \[[@B12]\]. Based on the clinical applications of*Sini* decoction, SDP was then developed by Sun \[[@B13]\]. The syndromes of SDP were correlated with numerous symptoms, such as a slow pulse, coldness on the extremities, continuous diarrhea with undigested cereal, and severe diarrhea, but no common profile exists. According to our survey of 300 senior clinical TCM practitioners, we obtained a common profile for SDP: (1) pulse feels deep or faint and (2) reversal cold of the extremities. We collected SDP patients with these 2 symptoms. In this study, 12 patients with SDP and 12 non-SDP individuals were recruited from Taipei City Hospital, Linsen Chinese Medicine Branch, Taiwan.

We extracted the total mRNA of PBMCs from the 24 individuals for microarray experiments. Twelve individuals (including 6 SDP patients and 6 non-SDP individuals) were used as the training set to identify the biomarkers that were screened using the hypothesis test for distinguishing the SDP and non-SDP groups. The remaining 12 individuals (including 6 SDP patients and 6 non-SDP individuals) were used as the test set to examine whether the identified biomarkers can distinguish the SDP and non-SDP groups. The test results indicated that the gene expression profiling by the biomarkers could effectively distinguish the 2 groups by using a hierarchical clustering algorithm.

Our results suggested the feasibility of using biomarkers extracted from the gene expressions of PBMCs in facilitating the diagnosis of TCM ZHENGs. Furthermore, the gene expression profiles of biomarkers could provide the possible molecular mechanisms of related TCM ZHENGs.

2. Materials and Methods {#sec2}
========================

2.1. Chinese Medicine Terminology {#sec2.1}
---------------------------------

All Chinese medicine terms used in this paper were in accordance with the*International Acupuncture Nomenclature* (IAN) proposed by WHO in 1991; if not available in IAN, the standard nomenclature proposed in the*WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region* \[[@B14]\] was adapted. These translated Chinese medicine terms are presented in italics in this paper.

2.2. Human Participants {#sec2.2}
-----------------------

The syndromes of SDP were associated with a slow, deep, and faint pulse that disappeared, coldness on the extremities, severe diarrhea, continuous diarrhea with undigested cereal, generalized pain, abdominal fullness, cold-fluid retention on the diaphragm, profuse sweating, severe spasms in the feet, tight clamping of the extremities, and reversal cold in both the hands and feet; however, no common profile exists. To obtain a common profile for SDP, we distributed questionnaires to 300 senior clinical TCM practitioners. Our questionnaire listed 41 symptoms related to SDP. In the survey, each senior clinical TCM practitioner assigned a score to each symptom, indicating the correlation between the symptom and SDP from high to low (5, 4, 3, 2, 1, and 0). We identified symptoms that collectively constituted a common SDP profile according to the frequency with which participating TCM practitioners assigned a score of 5 to the symptoms; the frequency threshold was set at higher than 35% of the returned surveys. We recruited SDP patients with the aforementioned symptoms. In this study, 12 SDP patients and 12 non-SDP individuals from Taipei City Hospital, Linsen Chinese Medicine Branch, Taiwan, were recruited. All of the individuals provided informed consent. The definition of healthy subject was diagnosed by western medicine rather different from TCM. It is difficult to diagnose healthy subject. Therefore, we consider substituting non-SDP patients for healthy subject. We try our best to collect non-SDP patients who are alike healthy subjects.

2.3. Blood Sample Collection {#sec2.3}
----------------------------

We phlebotomized 30 mL of human peripheral blood from each donor and then separated the blood into three 10 mL plastic whole blood tubes with spray-coated K2EDTA (Becton Dickenson, Franklin Lakes, NJ, USA). The blood was transferred to a 50 mL centrifuge tube. The PBMCs were then prepared from the 30 mL of peripheral blood through Ficoll-Hypaque density gradient centrifugation. The PBMCs were added to an RNA*later* RNA Stabilization Reagent (Qiagen, Valencia, CA, USA) and then placed into a bottle with liquid nitrogen. All of these procedures were performed immediately after the blood was collected at the laboratory of Taipei City Hospital, Linsen Chinese Medicine Branch, Taiwan. The isolated PBMCs were frozen, stored in a liquid nitrogen freezer, and transported to the microarray experimental laboratory at National Tsing Hua University, Hsinchu, Taiwan, for further microarray experiments.

2.4. RNA Extraction and Microarray Hybridization {#sec2.4}
------------------------------------------------

We extracted total RNA by using the RNeasy Mini Kit according to the manufacturer\'s protocol (Qiagen, Valencia, CA, USA). Total RNA quantity and quality were assessed using an ultraviolet absorption spectrophotometer at 260 and 280 nm. Subsequently, *α*- and *β*-globin mRNA were reduced from a portion of the total RNA samples by using the GLOBINclear*™* human kit (Ambion, Austin, TX, USA), according to the manufacturer\'s instructions, at the recommended start quantity of 10 *μ*g of total RNA. The quality of total RNA was evaluated using the Agilent 2100 bioanalyzer with the RNA 6000 Nano LabChip kit (Agilent Technologies, Palo Alto, CA, USA). Before reverse transcription, each RNA sample was spiked with a mixture of Arabidopsis mRNAs, which we called doping control. Fluorescence-labeled (Cy3, Cy5-3DNA Capture Reagent) cDNA was conducted using the 3DNA Array 900 labeling kit according to the manufacturer\'s protocols (Genisphere, Hatfield, PA, USA). Reverse transcription was performed using SuperScript II (Invitrogen, Carlsbad, CA, USA). Hybridization was performed at 65°C in a water bath for 16 to 18 h, and arrays were washed according to the manufacturer\'s protocol (Corning Life Sciences, New York, NY, USA). The arrays were scanned using GenePix 4000B scanner (Axon Instruments, Foster City, CA, USA).

2.5. Microarray Fabrication {#sec2.5}
---------------------------

A total of 9600 human cDNA clones were purchased from Incyte Genomics (Wilmington, DE, USA). These cDNAs were randomly selected from the IMAGE library. Resequencing was performed on these clones, and 7334 cDNAs were verified to have corrected DNA sequences. These 7334 sequence-verified human cDNAs (Incyte Genomics) and 10 Arabidopsis cDNAs (SpotReport*™* cDNA Array Validation System; Stratagene, La Jolla, CA, USA), serving as spike-in controls, and one housekeeping gene (*β*-actin), serving as a positive control, were arrayed on Corning UltraGAPS slides (Corning, Corning, NY, USA). These 7334 human cDNAs and 96 Arabidopsis cDNAs and housekeeping genes were spotted in quadruplicate on each array making a total of 32248 spots to enhance the statistical confidence in the gene expression data. Each array had 32,448 spots. The arrays were postprocessed according to the Corning UltraGAPS Coated Slides instruction manual.

2.6. Experimental Design {#sec2.6}
------------------------

Loop design, a type of statistical microarray experimental design, was adopted to construct an optimal design. The basic principles of optimal design are a balance among the factors, approximately equal sampling of varieties, and minimal distance between pairs of varieties \[[@B15]\]. Samples from 24 individuals were hybridized on 48 arrays based on the 2 loop designs presented in [Figure 1](#fig1){ref-type="fig"}. The individuals of samples L1A1, L1A2, L1A3, L1C1, L1C2, L1C3, L2A1, L2A2, L2A3, L2C1, L2C2, and L2C3 were SDP patients, and those of samples L1B1, L1B2, L1B3, L1D1, L1D2, L1D3, L2B1, L2B2, L2B3, L2D1, L2D2, and L2D3 were non-SDP individuals. Each arrow in the figure indicates a microarray hybridization experiment. The arrow heads and tails represent samples labeled with Cy5 (3DNA Capture Reagent) and Cy3 (3DNA Capture Reagent), respectively. The black solid circles stand for the SDP samples and the open circles stand for non-SDP samples. We used 12 individuals in Loop 1 experiments as the training set and the remaining 12 individuals in Loop 2 experiments as the test set.

2.7. Microarray Data Analysis and Statistical Analysis {#sec2.7}
------------------------------------------------------

Microarray data preprocessing, normalization, and statistical analysis were performed using the bioinformatics software suite Tsing Hua Engine for Microarray Experiment \[[@B16]\].

Spot-screening rules were applied to screen invalid spots on these arrays. The spot-screening rules for the data of Loop 1 (the training set) were as follows: (1) exclude the spots defined as "flag bad" or "absent" in all GenePix Results (GPR), (2) exclude the spots with diameters less than 100 *μ*m, (3) exclude the spots with a coefficient of variation (CV) of pixel intensity of over 100% in both channels, and (4) exclude the spots with signal to noise ratios (SNRs) in both channels were less than 2 in the training set microarray experiments. The SNR is defined as (*S* − *B*)/*B* (*S*: mean of pixel intensities of the signal; *B*: median pixel intensity of the background). The logarithm of the ratios for all valid spots on each array was normalized using global lowess normalization \[[@B17]\]. After the data were preprocessed, the normalized log ratios of the fluorescence intensity of each cDNA spot were analyzed using a log linear model, which was described in our previous study \[[@B18]\], to obtain the least-squares estimates $\hat{\lambda_{1}}$, $\hat{\lambda_{2}}$, $\hat{\lambda_{3}}$, $\hat{\lambda_{4}}$, $\hat{\lambda_{5}}$, $\hat{\lambda_{6}}$, $\hat{\lambda_{7}}$, $\hat{\lambda_{8}}$, $\hat{\lambda_{9}}$, $\hat{\lambda_{10}}$, $\hat{\lambda_{11}}$, and $\hat{\lambda_{12}}$ for the relative expressions among all of the samples. The relative expressions of sample *i* are defined as (expression of sample *i*)/(geometric average of the expression of all samples), for each gene, where *i* runs from 1 to 12. For the training set microarray data, 4951 genes satisfied the selection criteria of the spot-screening rules and log linear model. The selection criteria for the data of Loop 2 (the test set) are described in the subsequent subsection. The microarray data is available at GEO (GSE67090).

2.8. Searching Biomarkers to Distinguish SDP {#sec2.8}
--------------------------------------------

We used Loop 1 experiments as the training set and Loop 2 experiments as the test set. For the 4951 genes of Loop 1 (the training set), 192 genes were identified using an *F* test with null hypothesis *H* ~0~: ($\hat{\lambda_{1}} + \hat{\lambda_{3}} + \hat{\lambda_{5}} + \hat{\lambda_{7}} + \hat{\lambda_{9}} + \hat{\lambda_{11}}) - (\hat{\lambda_{2}} + \hat{\lambda_{4}} + \hat{\lambda_{6}} + \hat{\lambda_{8}} + \hat{\lambda_{10}} + \hat{\lambda_{12}}) = 0$, at a Bonferroni-adjusted significance level of 0.05/4951, where $\hat{\lambda_{1}}$, $\hat{\lambda_{3}}$, $\hat{\lambda_{5}}$, $\hat{\lambda_{7}}$, $\hat{\lambda_{9}}$, and $\hat{\lambda_{11}}$ were the least-squares estimates for the relative expressions of the SDP samples and $\hat{\lambda_{2}}$, $\hat{\lambda_{4}}$, $\hat{\lambda_{6}}$, $\hat{\lambda_{8}}$, $\hat{\lambda_{10}}$, and $\hat{\lambda_{12}}$ were the least-squares estimates for the relative expressions of the non-SDP samples.

The 192 biomarker genes were then used to distinguish the SDP and non-SDP groups of the test set. We applied the selection criteria to filter bad spots to perform an effective normalization and a log linear model. In order to include additional available genes to be tested, we relaxed the selection criteria of the spot-screening rules for the data of Loop 2 (the test set) as follows: (1) exclude the spots defined as "flag bad" or "absent" in all GPR files, (2) exclude the spots with diameters less than 50 *μ*m, (3) exclude the spots with a CV of pixel standard deviation of over 150% in both channels, and (4) exclude the spots with SNRs in either channel were less than 1 in the test microarray experiments. The logarithm of the ratios for all valid spots on each array was normalized under the same normalization conditions as those for the training set. We then used hierarchical clustering to verify whether the gene expression profiles of the 192 biomarker genes could classify the 12 test samples into 2 groups and how well they could distinguish the SDP patients and non-SDP individuals.

2.9. Functional Annotation and Enrichment Analysis {#sec2.9}
--------------------------------------------------

Functional annotation and enrichment analysis were accessed through the database for annotation, visualization, and integrated discovery (DAVID) \[[@B19]\], which performed a modified Fisher\'s exact test to identify overrepresented functions. DAVID is a widely employed web tool that provides a rapid means to understand the biological meaning of a long list of genes of interest. For any gene list, DAVID can map and convert identifiers (IDs) and accessions among different gene IDs. A long gene list can be reduced into biological theme-related groups of genes, for example, gene ontology (GO) \[[@B20]\] and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway \[[@B21]\].

The Entrez gene IDs of 192 biomarker genes were used as the gene ID for bioinformatics analysis. Biological processes of GO terms were used for functional annotation and enrichment analysis of these biomarker genes.

3. Results {#sec3}
==========

3.1. Questionnaires to Obtain a Common Profile for SDP {#sec3.1}
------------------------------------------------------

We distributed questionnaires to 300 senior clinical TCM practitioners, and 43 questionnaires were returned. Our questionnaire listed 41 symptoms related to SDP. In the survey, each senior clinical TCM practitioner assigned a score to each symptom, indicating the correlation between the symptom and SDP, from high to low (5, 4, 3, 2, 1, and 0). Based on the frequency with which participating TCM practitioners assigned a score of 5 to the symptoms, we identified symptoms that collectively constituted a common SDP profile ([Figure 2](#fig2){ref-type="fig"}). The frequency threshold was set at higher than 35% of the 43 returned surveys (i.e., symptoms assigned a score of 5 by at least 16 surveys). This process revealed 7 symptoms to form our symptom profile of SDP patients. By grouping related symptoms, we obtained a common profile for SDP as 2 sets of symptoms: (1) pulse feels deep or faint and (2) reversal cold of the extremities. We recruited SDP patients with the 2 sets of symptoms. In this study, 12 SDP patients and 12 non-SDP individuals were recruited from Taipei City Hospital, Linsen Chinese Medicine Branch, Taiwan. All of the participants provided informed consent.

3.2. Identifying Biomarker Genes from the Training Set Microarray Experiment {#sec3.2}
----------------------------------------------------------------------------

On the basis of the results for the 4951 genes of Loop 1 (the training set), 192 genes were identified ([Table 1](#tab1){ref-type="table"}) using an *F* test with null hypothesis *H* ~0~: $(\hat{\lambda_{1}} + \hat{\lambda_{3}} + \hat{\lambda_{5}} + \hat{\lambda_{7}} + \hat{\lambda_{9}} + \hat{\lambda_{11}}) - (\hat{\lambda_{2}} + \hat{\lambda_{4}} + \hat{\lambda_{6}} + \hat{\lambda_{8}} + \hat{\lambda_{10}} + \hat{\lambda_{12}}) = 0$, at a Bonferroni-adjusted significance level of 0.05/4951. By applying hierarchical clustering with Spearman distance and average linkage, the 12 training samples were appropriately separated into 2 groups, as shown in [Figure 3](#fig3){ref-type="fig"}. In [Figure 3](#fig3){ref-type="fig"}, the gene expression value used to do the clustering is the relative expressions of the labeled sample.

3.3. Distinguishing Power of the Biomarker Genes to the Test Set Microarray Experiment {#sec3.3}
--------------------------------------------------------------------------------------

The 192 biomarker genes identified in the training set experiments were then used to test the ability to distinguish the SDP patients and non-SDP individuals in the test set. To include additional available genes to be tested, we relaxed the selection criteria of the spot-screening rules for the data of the test set (Loop 2). The logarithm of the ratios for all valid spots on each array was normalized under the same normalization conditions as those for the training set. We then used hierarchical clustering to verify whether the gene expression profiles of the 192 biomarker genes could classify the 12 test samples into 2 groups and how well they could distinguish the SDP patients and non-SDP individuals. Under the same clustering conditions (i.e., hierarchical clustering with Spearman distance and average linkage), [Figure 4](#fig4){ref-type="fig"} showed that the 192 biomarker genes can classify the 12 test samples into 2 groups. One group comprised L2A2, L2A1, L2A3, L2C3, L2C2, and L2D1 samples and the other comprised L2D2, L2B3, L2D3, L2B2, L2C1, and L2B1 samples. Except for L2D1 and L2C1 samples, all of the samples were correctly grouped into SDP and non-SDP groups. In [Figure 4](#fig4){ref-type="fig"}, the gene expression value used to do the clustering is the relative expressions of the labeled sample. The microarray data of 4 biomarker genes from 7 samples were confirmed by quantitative PCR (qPCR). The correlation coefficients *r* between microarray data and qPCR for each gene are 0.73, 0.83, 0.93, and 0.76 ([Appendix A](#secA){ref-type="sec"}).

3.4. Functional Annotation and Enrichment Analysis Results for the 192 Biomarker Genes {#sec3.4}
--------------------------------------------------------------------------------------

The functional annotation and enrichment analysis were accessed using DAVID. Seventy-eight GO terms were enriched with a *P* value less than 0.05. All enriched GO terms are listed in [Appendix B](#secB){ref-type="sec"}. 78 GO terms were enriched with a *P* value of less than 0.05. We further applied 2 stringent criteria to filter the high-ranked GO terms: (1) GO terms containing more than 10 genes and (2) a *P* value of less than 0.01. Consequently, 11 GO terms were identified ([Table 2](#tab2){ref-type="table"}).

[Table 2](#tab2){ref-type="table"} showed that the 11 GO terms are substantially correlated with immune, inflammation, and hemopoiesis functions. In detail, the immune function includes defense response, immune response, response to bacterium, and immune system development. The inflammation function includes cytokine production regulation, behavior, cell activation, and cellular homeostasis. The hematopoiesis function includes hemopoietic or lymphoid organ development and hemopoiesis.

4. Discussion {#sec4}
=============

Of the 4951 genes of the training set, 192 genes were identified using an *F* test with null hypothesis. By applying hierarchical clustering with Spearman distance and average linkage, the 12 training samples were appropriately separated into SDP and non-SDP groups. The 192 biomarker genes were then used to distinguish the SDP patients and non-SDP individuals in the test set. Under the same clustering conditions, the 12 test samples were clustered into 2 groups. One group comprised L2A2, L2A1, L2A3, L2C3, L2C2, and L2D1 samples and the other comprised L2D2, L2B3, L2D3, L2B2, L2C1, and L2B1 samples. Except for L2D1 and L2C1 samples, all of the samples were correctly grouped into the SDP and non-SDP groups. Thus, we reviewed the original information of these 2 samples. L2C1 sample (classified as SDP according to TCM but clustered into the non-SDP group by using biomarkers) had a deep, rough, and rapid pulse and reversal cold of the extremities. Among the symptoms of L2C1 sample, reversal cold of the extremities matched the selected symptom of SDP; however, a deep, rough, and rapid pulse was inconsistent with a deep or faint pulse, a selected symptom for SDP. L2D1 sample (categorized as non-SDP according to TCM but clustered into the SDP group by using biomarkers) had a deep and tight pulse, which was particularly deep at the*guan* site (the guan is immediately central to the radial styloid at the wrist, where the tip of the physician\'s middle finger is placed), and reversal cold of the extremities. Among the symptoms of L2D1 sample, a deep and tight pulse, particularly at the guan site, did not meet the symptom of a deep or faint pulse, and the sample was thus classified as non-SDP according to TCM. However, reversal cold of the extremities matched the selected symptom of SDP. These findings indicate that, in classifying these 2 samples into SDP and non-SDP groups, uncertain areas exist. Nevertheless, determining biomarkers by using the mRNA profiling method can facilitate identifying the SDP group. Therefore, the traditional dialectical method of TCM is quite trustworthy.

The results of the functional annotation and enrichment analysis of 192 biomarker genes revealed that the 11 GO terms were substantially correlated with immune, inflammation, and hemopoiesis functions. Among the symptoms of SDP, a deep or faint pulse implied the insufficiency of *Qi* (in the field of medicine, *Qi* refers both to the refined nutritive substance that flows within the human body and to its functional activities). Insufficiency of *Qi* indicates the body\'s resistance against disease is weak. Pathogens can invade the human body easily, and viruses and bacteria could then cause inflammation easily.

5. Conclusion {#sec5}
=============

Our results provided the biomarker genes of SDP, which was first mentioned in*Shang Han Za Bing Lun*. The results provide molecular evidence for TCM in the ZHENGs differentiation of SDP. Using mRNA profiling experiments on patients\' PBMCs to discover biomarker genes to test an unknown group of individuals can effectively identify a specific ZHENG. We hope that the mRNA profiling method will become a model for TCM physicians in diagnosis and assist TCM practitioners in evaluating the curative effect of the medication.

A. {#secA}
==

The microarray data of 4 biomarker genes from 7 samples were confirmed by quantitative PCR (qPCR). The correlation plots between microarray data and qPCR data are shown in [Table 3](#tab3){ref-type="table"}. The correlation coefficients *r* for each gene are 0.73 (GNG2), 0.83 (RUNX3), 0.93 (CST7), and 0.76 (MNDA), shown in [Figure 5](#fig5){ref-type="fig"}.

B. {#secB}
==

The complete list of all enriched GO terms for 192 biomarker genes (sorted according to *P* value) is shown in [Table 4](#tab4){ref-type="table"}.
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![Experimental designs of Loop 1 (for the training set) and Loop 2 (for the test set). Each arrow indicates a microarray hybridization experiment. The arrow heads and tails represent samples labeled with Cy5 and Cy3, respectively. The black solid circles stand for the SDP samples and the open circles stand for non-SDP samples. Loop 1 is the experimental design for the training set of 12 individuals. Loop 2 is the experimental design for the test set of the other 12 individuals. The annotations of samples in Loop 1 and Loop 2 are shown below each loop.](ECAM2016-8239817.001){#fig1}

![Frequency with which survey symptoms were assigned a score of 5 in determining the SDP profile.](ECAM2016-8239817.002){#fig2}

![192 genes, identified using the *F* test at a Bonferroni-adjusted significance level of 0.05/4951, were clustered into 2 groups. By applying hierarchical clustering with Spearman distance and average linkage, the 12 training samples were appropriately separated into 2 groups according to the 192 marker genes. Samples L1C2, L1A3, L1C3, L1A1, L1C1, and L1A2 comprised the SDP group, and samples L1D2, L1B3, L1D3, L1D1, L1B1, and L1B2 comprised the non-SDP group. In this figure, the gene expression value used to do the clustering is the relative expressions of the labeled sample.](ECAM2016-8239817.003){#fig3}

![Hierarchical clustering results for the 12 test samples. Under the same clustering conditions (i.e., hierarchical clustering with Spearman distance and average linkage), the gene expression profiles of the 192 marker genes classified the 12 test samples into 2 groups. One group consisted of the L2A2, L2A1, L2A3, L2C3, L2C2, and L2D1 samples and the other consisted of the L2D2, L2B3, L2D3, L2B2, L2C1, and L2B1 samples. Except for the L2D1 and L2C1 samples, all of the samples were correctly grouped into SDP and non-SDP groups. In this figure, the gene expression values that used to do the clustering are the relative expressions of the labeled sample.](ECAM2016-8239817.004){#fig4}

![The correlation coefficients *r* for each gene are 0.73 (GNG2), 0.83 (RUNX3), 0.93 (CST7), and 0.76 (MNDA).](ECAM2016-8239817.005){#fig5}

###### 

The 192 biomarker genes identified using an *F* test with null hypothesis *H* ~0~: $(\hat{\lambda_{1}} + \hat{\lambda_{3}} + \hat{\lambda_{5}} + \hat{\lambda_{7}} + \hat{\lambda_{9}} + \hat{\lambda_{11}}) - (\hat{\lambda_{2}} + \hat{\lambda_{4}} + \hat{\lambda_{6}} + \hat{\lambda_{8}} + \hat{\lambda_{10}} + \hat{\lambda_{12}}) = 0$, at a Bonferroni-adjusted significance level of 0.05/4951.

  Gene name                                           
  -------------- ----------- ----------- ----------- --------------
  ABHD3          ABI2        ACSM2B      ACTB        AGFG1
  AKAP9          ARG1        ARID5A      ATP1B3      ATP6AP2
  ATP6V0B        BLZF1       BPGM        C11orf79    C12orf24
  C12orf32       C17orf91    C6orf106    CAPN1       CBARA1
  CCL18          CCL5        CD1D        CD24        CD40
  CD44           CD83        CD8A        CD93        CDC42
  CDC42SE2       CLDN1       COMT        COX10       CP
  CREM           CST7        CXCL9       DEFA1       DEFA3
  DEFA4          DENND2D     DGCR6L      DLG2        DUSP6
  EEF2           EIF3E       EIF3I       EPAS1       EXOSC9
  FAM113B        FAM175B     FCER1A      FLNB        FMOD
  FOLR3          FOS         FOSB        FYN         GCA
  GIMAP1         GLRX        GNG11       GNG2        GNLY
  GPR56          GSTA2       GTF2E1      GZMA        H3F3B
  HERPUD1        HIST1H2AC   HIST1H2BD   HIST1H2BG   HIST1H2BJ
  HIST2H2AA3     HLA-A       HLA-DMA     HLA-DQB1    HLA-DRB1
  HLA-G          Hs.282050   Hs.467411   Hs.534061   Hs.586682
  Hs.591807      Hs.599359   Hs.655903   Hs.674438   Hs.88605
  HSP90B1        HSPA1A      HTATIP2     HTR7P1      ID2
  IFIT1          IL10RA      IL15RA      IL1B        IL32
  JARID1C        KIF3C       KLF10       KLF6        LCP1
  LNP1           LOC400027   LOC729776   LTB         LYRM1
  MAPK13         MBP         MCM3AP      MEST        MLH3
  MNDA           MRPL3       MRPL49      MTMR6       MYL6
  NCRNA00084     NHEDC2      NPY         NUCB1       NUDT16
  NUP93          ORM1        PACS1       PCDH8       PDE4B
  PEA15          PF4         PLAUR       PNLIPRP2    POLR1C
  POLR2D         POU2F2      PPBP        PPP1R12B    PPP1R7
  PPP2R2A        PPRC1       PPT1        PRL         PSMC6
  RAB4A          RARRES3     RGS18       RGS2        RHOQ
  RNF40          RNPEP       RPL41       RPS11       RPS24
  RPS27          RPS4X       RPS4Y1      RUNX3       S1PR5
  SEC22B         SELL        SERPINE2    SFRS1       SH2B3
  SH3D19         SHCBP1      SLC2A3P1    SOD2        SPTY2D1
  SRGN           STX8        SYTL2       TADA3L      TARP
  THBS1          TIMP1       TMEM176A    TNFAIP8L2   TPCN1
  TRA@           TRAPPC1     TRMT11      VIM         VPS13D
  WDR42A         WIZ         XPNPEP1     YARS        Unknown^*∗*^
  Unknown^*∗*^   ZNF286A                              

^*∗*^The sequence of the clone was not yet identified in the BLAST.

###### 

The 11 enriched GO terms for 192 biomarker genes (sorted according to *P* value).

  GO term      Description                                 \# gene   *P* value
  ------------ ------------------------------------------- --------- -----------
  GO:0006952   Defense response                            24        0.000000
  GO:0006955   Immune response                             24        0.000002
  GO:0009617   Response to bacterium                       11        0.000088
  GO:0001817   Regulation of cytokine production           11        0.000172
  GO:0048534   Hemopoietic or lymphoid organ development   13        0.000562
  GO:0030097   Hemopoiesis                                 12        0.000999
  GO:0002520   Immune system development                   13        0.001183
  GO:0007610   Behavior                                    14        0.004162
  GO:0006412   Translation                                 12        0.004210
  GO:0001775   Cell activation                             11        0.008090
  GO:0019725   Cellular homeostasis                        13        0.009574

###### 

The correlation plots between microarray data and qPCR data.

  -----------------------------------------------------------------------------
  Genes          Samples        Microarray data   qPCR data             
  -------------- -------------- ----------------- ----------- --------- -------
  GNG2           \(a\) L2A1 \   0.572 \           0.476       −0.35 \   0.49
                 (b) L2B2       0.097                         0.14      

  \(a\) L2B2 \   0.097 \        −0.139            0.14 \      0.66      
  (b) L2A2       0.235                            0.80                  

  \(a\) L2A2 \   0.235 \        0.625             0.80 \      0.95      
  (b) L2D1       −0.389                           1.75                  

  \(a\) L2D1 \   −0.389 \       −0.167            1.75 \      −1.25     
  (b) L2C2       −0.222                           0.50                  

  \(a\) L2C2 \   −0.222 \       0.035             0.50 \      0.71      
  (b) L2D2       −0.258                           1.21                  

  \(a\) L2D2 \   −0.258 \       −0.388            1.21 \      −0.54     
  (b) L2D3       0.131                            0.67                  

  \(a\) L2D3 \   0.131 \        −0.442            0.67 \      −1.02     
  (b) L2A1       0.572                            −0.35                 

                                                                        

  RUNX3          \(a\) L2A1 \   0.835 \           0.858       1.39 \    1.10
                 (b) L2B2       −0.022                        2.49      

  \(a\) L2B2 \   −0.022 \       0.020             2.49 \      0.32      
  (b) L2A2       −0.042                           2.81                  

  \(a\) L2A2 \   −0.042 \       0.057             2.81 \      0.04      
  (b) L2D1       −0.099                           2.85                  

  \(a\) L2D1 \   −0.099 \       0.159             2.85 \      −0.48     
  (b) L2C2       −0.258                           2.37                  

  \(a\) L2C2 \   −0.258 \       −0.068            2.37 \      0.49      
  (b) L2D2       −0.190                           2.86                  

  \(a\) L2D2 \   −0.190 \       −0.385            2.86 \      −0.49     
  (b) L2D3       0.196                            2.37                  

  \(a\) L2D3 \   0.196 \        −0.640            2.37 \      −0.98     
  (b) L2A1       0.835                            1.39                  

                                                                        

  CST7           \(a\) L2A1 \   1.301 \           1.076       −1.65 \   0.75
                 (b) L2B2       0.224                         −0.90     

  \(a\) L2B2 \   0.224 \        −0.268            −0.90 \     0.18      
  (b) L2A2       0.493                            −0.72                 

  \(a\) L2A2 \   0.493 \        0.946             −0.72 \     0.76      
  (b) L2D1       −0.454                           0.04                  

  \(a\) L2D1 \   −0.454 \       −0.039            0.04 \      −0.05     
  (b) L2C2       −0.414                           −0.01                 

  \(a\) L2C2 \   −0.414 \       −0.089            −0.01 \     0.24      
  (b) L2D2       −0.325                           0.23                  

  \(a\) L2D2 \   −0.325 \       −0.626            0.23 \      −0.85     
  (b) L2D3       0.300                            −0.62                 

  \(a\) L2D3 \   0.300 \        −1.000            −0.62 \     −1.03     
  (b) L2A1       1.301                            −1.65                 

                                                                        

  MNDA           \(a\) L2A1 \   −1.136 \          −1.449      2.29 \    −1.53
                 (b) L2B2       0.313                         0.76      

  \(a\) L2B2 \   0.313 \        0.542             0.76 \      1.12      
  (b) L2A2       −0.229                           1.88                  

  \(a\) L2A2 \   −0.229 \       −0.044            1.88 \      −0.57     
  (b) L2D1       −0.185                           1.31                  

  \(a\) L2D1 \   −0.185 \       −0.170            1.31 \      −1.39     
  (b) L2C2       −0.015                           −0.08                 

  \(a\) L2C2 \   −0.015 \       −0.365            −0.08 \     0.25      
  (b) L2D2       0.349                            0.17                  

  \(a\) L2D2 \   0.349 \        −0.008            0.17 \      0.93      
  (b) L2D3       0.357                            1.10                  

  \(a\) L2D3 \   0.357 \        1.493             1.10 \      1.19      
  (b) L2A1       −1.136                           2.29                  
  -----------------------------------------------------------------------------

###### 

The complete list of all enriched GO terms for 192 biomarker genes (sorted according to *P* value).

  GO term      Description                                                                                                                                        \# gene   *P* value
  ------------ -------------------------------------------------------------------------------------------------------------------------------------------------- --------- -----------
  GO:0006952   Defense response                                                                                                                                   24        0.000000
  GO:0006955   Immune response                                                                                                                                    24        0.000002
  GO:0019882   Antigen processing and presentation                                                                                                                7         0.000073
  GO:0009617   Response to bacterium                                                                                                                              11        0.000088
  GO:0006968   Cellular defense response                                                                                                                          7         0.000149
  GO:0001817   Regulation of cytokine production                                                                                                                  11        0.000172
  GO:0048534   Hemopoietic or lymphoid organ development                                                                                                          13        0.000562
  GO:0030097   Hemopoiesis                                                                                                                                        12        0.000999
  GO:0002520   Immune system development                                                                                                                          13        0.001183
  GO:0002696   Positive regulation of leukocyte activation                                                                                                        8         0.001499
  GO:0001819   Positive regulation of cytokine production                                                                                                         7         0.001573
  GO:0050867   Positive regulation of cell activation                                                                                                             8         0.002053
  GO:0007610   Behavior                                                                                                                                           14        0.004162
  GO:0002763   Positive regulation of myeloid leukocyte differentiation                                                                                           4         0.004167
  GO:0006412   Translation                                                                                                                                        12        0.004210
  GO:0002684   Positive regulation of immune system process                                                                                                       10        0.006451
  GO:0006414   Translational elongation                                                                                                                           7         0.006467
  GO:0002822   Regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains            5         0.007075
  GO:0048584   Positive regulation of response to stimulus                                                                                                        10        0.007697
  GO:0001775   Cell activation                                                                                                                                    11        0.008090
  GO:0051240   Positive regulation of multicellular organism process                                                                                              10        0.008151
  GO:0002819   Regulation of adaptive immune response                                                                                                             5         0.008161
  GO:0030162   Regulation of proteolysis                                                                                                                          5         0.008161
  GO:0001818   Negative regulation of cytokine production                                                                                                         4         0.008578
  GO:0002824   Positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains   4         0.008578
  GO:0002544   Chronic inflammatory response                                                                                                                      3         0.009217
  GO:0010829   Negative regulation of glucose transport                                                                                                           3         0.009217
  GO:0050832   Defense response to fungus                                                                                                                         3         0.009217
  GO:0051043   Regulation of membrane protein ectodomain proteolysis                                                                                              3         0.009217
  GO:0002694   Regulation of leukocyte activation                                                                                                                 8         0.009343
  GO:0002706   Regulation of lymphocyte mediated immunity                                                                                                         5         0.009351
  GO:0019725   Cellular homeostasis                                                                                                                               13        0.009574
  GO:0002821   Positive regulation of adaptive immune response                                                                                                    4         0.010479
  GO:0042742   Defense response to bacterium                                                                                                                      5         0.010649
  GO:0042592   Homeostatic process                                                                                                                                18        0.011731
  GO:0006873   Cellular ion homeostasis                                                                                                                           11        0.012021
  GO:0050865   Regulation of cell activation                                                                                                                      8         0.012239
  GO:0009611   Response to wounding                                                                                                                               15        0.012528
  GO:0007267   Cell-cell signaling                                                                                                                                15        0.013447
  GO:0050778   Positive regulation of immune response                                                                                                             7         0.013518
  GO:0031640   Killing of cells of another organism                                                                                                               3         0.013542
  GO:0055082   Cellular chemical homeostasis                                                                                                                      11        0.013819
  GO:0002705   Positive regulation of leukocyte mediated immunity                                                                                                 4         0.014959
  GO:0002708   Positive regulation of lymphocyte mediated immunity                                                                                                4         0.014959
  GO:0010827   Regulation of glucose transport                                                                                                                    4         0.014959
  GO:0034101   Erythrocyte homeostasis                                                                                                                            5         0.015220
  GO:0030098   Lymphocyte differentiation                                                                                                                         6         0.016523
  GO:0051251   Positive regulation of lymphocyte activation                                                                                                       6         0.016523
  GO:0050801   Ion homeostasis                                                                                                                                    11        0.017255
  GO:0045639   Positive regulation of myeloid cell differentiation                                                                                                4         0.017545
  GO:0002703   Regulation of leukocyte mediated immunity                                                                                                          5         0.018862
  GO:0006935   Chemotaxis                                                                                                                                         7         0.020473
  GO:0042330   Taxis                                                                                                                                              7         0.020473
  GO:0045765   Regulation of angiogenesis                                                                                                                         5         0.020868
  GO:0006954   Inflammatory response                                                                                                                              10        0.021243
  GO:0046649   Lymphocyte activation                                                                                                                              8         0.024760
  GO:0045321   Leukocyte activation                                                                                                                               9         0.026088
  GO:0002761   Regulation of myeloid leukocyte differentiation                                                                                                    4         0.026706
  GO:0050870   Positive regulation of T cell activation                                                                                                           5         0.030175
  GO:0048872   Homeostasis of number of cells                                                                                                                     6         0.030221
  GO:0009620   Response to fungus                                                                                                                                 3         0.030551
  GO:0032655   Regulation of interleukin-12 production                                                                                                            3         0.030551
  GO:0031349   Positive regulation of defense response                                                                                                            5         0.032829
  GO:0002699   Positive regulation of immune effectors process                                                                                                    4         0.033982
  GO:0032103   Positive regulation of response to external stimulus                                                                                               5         0.035615
  GO:0048878   Chemical homeostasis                                                                                                                               12        0.036704
  GO:0002504   Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II                                                          3         0.037413
  GO:0016525   Negative regulation of angiogenesis                                                                                                                3         0.037413
  GO:0050850   Positive regulation of calcium-mediated signaling                                                                                                  3         0.037413
  GO:0006928   Cell motion                                                                                                                                        13        0.037784
  GO:0006334   Nucleosome assembly                                                                                                                                4         0.037967
  GO:0031497   Chromatin assembly                                                                                                                                 4         0.037967
  GO:0048002   Antigen processing and presentation of peptide antigen                                                                                             3         0.044801
  GO:0010033   Response to organic substance                                                                                                                      18        0.044896
  GO:0030218   Erythrocyte differentiation                                                                                                                        4         0.046616
  GO:0065004   Protein-DNA complex assembly                                                                                                                       4         0.046616
  GO:0002521   Leukocyte differentiation                                                                                                                          6         0.046793
  GO:0014070   Response to organic cyclic substance                                                                                                               6         0.049526
  GO:0002237   Response to molecule of bacterial origin                                                                                                           5         0.051544
  GO:0007626   Locomotory behavior                                                                                                                                8         0.052288
  GO:0055080   Cation homeostasis                                                                                                                                 8         0.052288
  GO:0050848   Regulation of calcium-mediated signaling                                                                                                           3         0.052676
  GO:0051249   Regulation of lymphocyte activation                                                                                                                6         0.055270
  GO:0034728   Nucleosome organization                                                                                                                            4         0.056149
  GO:0045619   Regulation of lymphocyte differentiation                                                                                                           4         0.056149
  GO:0002697   Regulation of immune effectors process                                                                                                             5         0.058846
  GO:0002712   Regulation of B cell mediated immunity                                                                                                             3         0.060999
  GO:0002889   Regulation of immunoglobulin mediated immune response                                                                                              3         0.060999
  GO:0051235   Maintenance of location                                                                                                                            4         0.061237
  GO:0032914   Positive regulation of transforming growth factor-beta 1 production                                                                                2         0.061881
  GO:0045651   Positive regulation of macrophage differentiation                                                                                                  2         0.061881
  GO:0007611   Learning or memory                                                                                                                                 5         0.062693
  GO:0008285   Negative regulation of cell proliferation                                                                                                          10        0.063328
  GO:0051241   Negative regulation of multicellular organism process                                                                                              6         0.064581
  GO:0051789   Response to protein stimulus                                                                                                                       5         0.066670
  GO:0016192   Vesicle-mediated transport                                                                                                                         13        0.067653
  GO:0042060   Wound healing                                                                                                                                      7         0.068209
  GO:0001906   Cell killing                                                                                                                                       3         0.069736
  GO:0046635   Positive regulation of alpha-beta T cell activation                                                                                                3         0.069736
  GO:0051094   Positive regulation of developmental process                                                                                                       9         0.072195
  GO:0050863   Regulation of T cell activation                                                                                                                    5         0.075009
  GO:0050900   Leukocyte migration                                                                                                                                4         0.077725
  GO:0009895   Negative regulation of catabolic process                                                                                                           3         0.078852
  GO:0046634   Regulation of alpha-beta T cell activation                                                                                                         3         0.078852
  GO:0030099   Myeloid cell differentiation                                                                                                                       5         0.079368
  GO:0055066   Di-, tri-valent inorganic cation homeostasis                                                                                                       7         0.080251
  GO:0006323   DNA packaging                                                                                                                                      4         0.083611
  GO:0030217   T cell differentiation                                                                                                                             4         0.083611
  GO:0043066   Negative regulation of apoptosis                                                                                                                   10        0.085435
  GO:0046324   Regulation of glucose import                                                                                                                       3         0.088316
  GO:0002863   Positive regulation of inflammatory response to antigenic stimulus                                                                                 2         0.091380
  GO:0032891   Negative regulation of organic acid transport                                                                                                      2         0.091380
  GO:0032908   Regulation of transforming growth factor-beta 1 production                                                                                         2         0.091380
  GO:0051918   Negative regulation of fibrinolysis                                                                                                                2         0.091380
  GO:0043069   Negative regulation of programmed cell death                                                                                                       10        0.092873
  GO:0060548   Negative regulation of cell death                                                                                                                  10        0.095435
  GO:0045637   Regulation of myeloid cell differentiation                                                                                                         4         0.095934
  GO:0030003   Cellular cation homeostasis                                                                                                                        7         0.096877
  GO:0045582   Positive regulation of T cell differentiation                                                                                                      3         0.098097
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